Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3019% above fair value
$1.34−0.26 (-16.51%)
Close on Nov 12, 2026Market cap $160.56MP/E –Yield –
Fate Therapeutics statistics
77 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.
Important dates
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Last ex-dividend date
- No dividends
- Fundamentals through
- Sep 30, 2026
- Share price as of
- Nov 12, 2026
Valuation ratiosIndustry
- P/TBV Ratio
- 1.21
- 2.29
Enterprise valuationIndustry
- EV / Sales
- 4.52
- 2.60
Share statisticsIndustry
- Shares Change (YoY)
- 2.03%
- 10.9%
- Shares Change (QoQ)
- 4.15%
- 0.51%
- Float
- 89M
- 49M
- Shares Held by Insiders
- 25.7%
- 12.1%
- Shares Held by Institutions
- 59.9%
- 56.4%
Short sellingIndustry
- Short Interest
- 10M
- –
- Short Interest Change
- -6.08%
- -0.76%
- Short % of Float
- 11.2%
- 9.04%
- Short % of Shares Outstanding
- 8.32%
- 6.30%
- Days to Cover
- 8.32
- 5.13
Stock price statisticsIndustry
- 52-Week High
- $3.23
- –
- 52-Week Low
- $0.95
- –
- 20-Day Moving Average
- $1.95
- –
- 50-Day Moving Average
- $2.18
- –
- 200-Day Moving Average
- $1.99
- –
- Average True Range (14)
- $0.17
- –
- Price Change (1 Week)
- -27.6%
- 1.51%
- Price Change (1 Month)
- -30.9%
- -2.35%
- Price Change (3 Months)
- -47.9%
- -21.1%
- Price Change (6 Months)
- -29.5%
- -22.6%
- Price Change (YTD)
- 36.4%
- -22.6%
- Price Change (1 Year)
- 19.6%
- -20.7%
- Price Change (3 Years)
- -32.7%
- -27.4%
- Price Change (5 Years)
- -97.6%
- -77.3%
- Price Change (10 Years)
- -54.3%
- -62.7%
- Average Volume (10 Days)
- 2M
- –
- Average Volume (20 Days)
- 2M
- –
- Average Volume (90 Days)
- 2M
- –
- Relative Volume
- 2.12
- 0.79
- Relative Strength Index (14)
- 24.6
- 44.7
- Volatility (1 Year)
- 91.0%
- 80.4%
- Beta (5 Years)
- 2.40
- 1.07
MarginsIndustry
- EBITDA Margin
- -2519.2%
- -27.7%
- FCF Margin
- -2249.4%
- -9.20%
Returns on capitalIndustry
- Return on Equity (ROE)
- -67.8%
- -51.2%
- Return on Assets (ROA)
- -42.8%
- -40.6%
- Return on Invested Capital (ROIC)
- -1647.3%
- -32.9%
- Return on Capital Employed (ROCE)
- -63.8%
- -38.0%
Financial positionIndustry
- Current Ratio
- 4.41
- 3.30
- Quick Ratio
- 4.27
- 2.42
GrowthIndustry
- Revenue Growth (YoY)
- -33.4%
- 7.01%
- Revenue Growth (3Y CAGR)
- -59.0%
- 2.25%
- Revenue Growth (5Y CAGR)
- -26.7%
- 6.41%
EfficiencyIndustry
- Asset Turnover
- 0.02
- 0.40
- Revenue Per Employee
- $29.50K
- $429.29K
- Profits Per Employee
- -$772.88K
- -$683.67K
- Employee Count
- 161
- 75
- WACC
- 17.0%
- 10.1%
Income statement (TTM)Industry
Balance sheetIndustry
- Net Cash (Debt)
- $139.10M
- $17.46M
- Net Cash Per Share
- $1.16
- $0.72
- Equity (Book Value)
- $133.03M
- $53.27M
- Book Value Per Share
- $1.11
- $1.50
- Tangible Book Value
- $133.03M
- $26.82M
- Working Capital
- $111.57M
- $79.47M
Cash flow (TTM)Industry
- Capital Expenditures
- -$1.51M
- -$944.00K
- FCF Per Share
- -$0.89
- -$0.42
Dividends and yieldsIndustry
- Earnings Yield
- -77.5%
- -20.8%
- FCF Yield
- -66.5%
- -9.58%
Scores and fair valueIndustry
- Altman Z-Score
- -9.87
- 0.30
- Piotroski F-Score
- 3
- 4
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | FATE | S&P 500 | Difference | FATE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.1% | -2.7% | −34.4 pts | ||
| 3 months | -50.7% | -1.7% | −49.0 pts | ||
| Year to date | +36.4% | +11.9% | +24.5 pts | ||
| 1 year | +28.8% | +12.0% | +16.9 pts | ||
| 3 years | -35.0% | +78.2% | −113.1 pts | -13.4% | +21.2% |
| 5 years | -97.6% | +73.2% | −170.8 pts | -52.6% | +11.6% |
| 10 years | -54.3% | +309.6% | −363.9 pts | -7.5% | +15.1% |
Short interest
Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.
10M FATE shares were sold short on Oct 30, 2026, down 6.1% from the previous report, or 11.20% of the shares available to trade. At recent volumes it would take 8.3 days to buy them back. Over the last 20 sessions, 53.9% of the volume reported to FINRA was short selling.
| Settlement date | Shares short | Change | Avg. daily volume | Days to cover |
|---|---|---|---|---|
| Oct 30, 2026 | 9,972,851 | -6.1% | 1,199,352 | 8.3 |
| Oct 15, 2026 | 10,618,410 | -1.3% | 1,216,826 | 8.7 |
| Sep 30, 2026 | 10,759,313 | +14.6% | 2,041,291 | 5.3 |
| Sep 15, 2026 | 9,386,451 | +3.0% | 893,769 | 10.5 |
| Aug 31, 2026 | 9,111,011 | +7.1% | 1,462,950 | 6.2 |
| Aug 14, 2026 | 8,508,135 | +10.8% | 2,593,866 | 3.3 |
| Jul 31, 2026 | 7,679,112 | +5.0% | 1,675,422 | 4.6 |
| Jul 15, 2026 | 7,315,037 | -1.6% | 3,690,730 | 2.0 |
| Jun 30, 2026 | 7,432,049 | -31.3% | 6,076,171 | 1.2 |
| Jun 15, 2026 | 10,821,669 | +1.2% | 3,616,075 | 3.0 |
| May 29, 2026 | 10,697,112 | +10.0% | 5,176,029 | 2.1 |
| May 15, 2026 | 9,728,302 | -5.1% | 4,914,298 | 2.0 |
Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.
See a number that looks wrong?